Review Article
A Meta-Analysis on the Seroprevalence of Parvovirus B19 among Patients with Sickle Cell Disease
Table 1
Seroprevalence of B19 V IgG stratified according to subgroups.
| | Subgroup | No. of studies | Patients, n/N | Pooled prevalence (%) | I2 | t value; degree of freedom ( value) | X2 ( value) |
| | Continent | Africa | 7 | 569/1008 | 55.5% | 97.04% | −3.1 ; 6 (P = ) | 140.4 () | | Americas | 6 | 546/1594 | 39.0% | 96.09% | −3.2 ; 5 () | | | Asia | 2 | 160/288 | 54.9% | 97.41% | −2.2 ; 1 (P = ) | |
| | Age group | Children | 9 | 857/2189 | 42.0% | 98.00% | −4.5 ; 8 () | 102.1 () | | All | 5 | 310/551 | 56.5% | 86.00% | −5.9 ; 5 () | | | Adults | 1 | 108/150 | 72.0% | Na | Na | |
|
|
